CD38 and plasma cell myeloma: Lenalidomide upregulated the expression of CD38 on the surface of myeloma cells (29), and the combination of Daratumumab with lenalidomide/dexamethasone (30) or other drugs such as bortezomib/dexamethasone are continuously carried out and they can significantly improve the clinical outcomes of patients (29).